Shares of Veracyte (VCYT) surged 16.18% in intraday trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The genomic diagnostics company reported better-than-expected revenue and earnings, significantly outperforming analyst estimates and demonstrating strong growth across its key business segments.

Veracyte announced total revenue of $131.9 million for Q3, representing a 14% year-over-year increase and beating analyst estimates of $124.6 million. The company's testing revenue, which accounts for the bulk of its business, grew by an impressive 17% to $127.8 million, fueled by strong demand for its Decipher Prostate and Afirma tests. Earnings per share came in at $0.51, significantly outperforming the analyst consensus estimate of $0.13 and marking a 54.55% increase from the same period last year.

Adding to investor optimism, Veracyte raised its full-year 2025 guidance. The company now expects total revenue between $506 million and $510 million, up from its previous forecast. Additionally, Veracyte increased its adjusted EBITDA guidance to over 25% of revenue, signaling improved profitability. The strong quarterly performance, coupled with the upward revision in guidance, has bolstered investor confidence in Veracyte's growth trajectory and operational execution, leading to the significant stock price appreciation during the trading session.